3.
A:
It received approval for emergency use only.
B:
It met WHO standards for quality, safety, and efficacy, receiving prequalification.
C:
It was granted funding support by Gavi, the Vaccine Alliance.
D:
It demonstrated effectiveness against various mosquito-borne diseases.
The answer is: B